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INTRODUCTION
Stroke is responsible for around 11% of 
all deaths worldwide.1 Approximately 
17 million incidences of first-time stroke 
occurred in 2010.2 Every year, stroke causes 
in the region of 5.7 million deaths.3
Reducing the stroke burden and risk 
of further cerebrovascular events can 
be achieved through implementing 
cholesterol lowering and blood pressure 
lowering therapies.4–6 However, prevention 
is dependent on the survivors adherence 
to medication. Estimates suggest around 
50% of patients with chronic disease are 
nonadherent,7 resulting in significant 
adverse outcomes as well as increased 
morbidity and mortality.8
Medication adherence is suboptimal 
among survivors of stroke. A systematic 
review exploring whether adherence to 
cardiovascular therapies influenced the risk 
of cardiovascular disease (CVD) concluded 
that a significant proportion of people did not 
adhere to cardiovascular medications and 
as much as 9% of all CVD events in Europe 
could be attributed to poor adherence to 
vascular medications alone.9 Elsewhere, 
De Simoni and colleagues found few trial 
interventions supporting the effect of 
medication adherence on lowering blood 
pressure in survivors of stroke or transient 
ischaemic attack (TIA). Trials, which included 
highly-selected stroke populations, largely 
excluded patients with any significant 
cognitive deficit and did not account for the 
caregiver role in the lives of stroke patients.10
There have been few studies on adherence 
barriers in stroke. Kronish and colleagues 
identified concerns about medication and 
knowledge of stroke prevention therapies 
as important barriers among survivors of 
stroke.11 In another study, beliefs about 
medication, side effects of medication and 
the inadequate provision of information 
were considered important barriers to 
medication adherence.12 Further evidence 
on factors affecting adherence after stroke 
could address the poor uptake of these 
medications. The aim of this study was to 
use qualitative interviews to explore the 
barriers to medication adherence in UK 
general practice.
METHOD
Design and participants
Interviews were conducted with patients on 
the stroke registers of five GP surgeries, 
together with their carers where relevant, 
and one GP from each practice. A list of 
patients aged >55 years, with a history of 
stroke or/TIA was compiled and sent to the 
GPs for review. Anyone who was considered 
unfit to participate in the research (that 
is, was seriously ill or terminally ill) was 
excluded and not approached by the practice. 
To achieve a maximum spread of age, 
socioeconomic status (Indices of Multiple 
Deprivation score13), sex and disability (using 
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modified Rankin score14), purposive sampling 
was undertaken. Initially, 25 patients from 
each practice were approached by letter. 
Positive responders were telephoned to 
confirm their attendance and the presence of 
a caregiver at the interview. The final number 
of interviews was determined by the point of 
data saturation.
Semi-structured interviews
Semi-structured interviews provided an 
opportunity for in-depth investigation of 
people’s personal perspectives, using an 
open-ended line of questioning, which 
defined the area to be explored.15 A topic 
schedule guided the line of questioning and 
prompts encouraged further discussion 
(Appendix 1). Two survivors piloted the patient 
topic guides and recommendations were 
incorporated. A clinical researcher provided 
feedback on the GP topic guide. Interviews 
were conducted in the patient’s home or 
the practice. Discussion topics included 
attitudes to secondary prevention care, 
medication beliefs, adherence to treatment, 
carer role, GPs attitudes towards current 
practice, and barriers to uptake. Interviews 
were conducted between June 2013 and 
February 2014, lasted 1.0–1.5 hours and 
were audiotaped and transcribed.
Data analysis
To ensure reliability of interpretation, 
transcripts were initially read by one of 
the authors and inaccuracies resolved by 
listening to the recordings. NVivo 9 was used 
to organise, code, and manage the data. 
Transcripts were entered into the program 
and coded, using grounded theory and 
followed a constant comparative analysis16 
approach, in which key points were identified 
from the data and coded individually. An 
iterative process of data collection and data 
analysis was undertaken. Initially, chunks 
of data were coded. Codes were then 
grouped into similar concepts and themes 
and categories were formed. A process of 
identification and refinement of categories 
followed. As groups were compared further, 
more abstract categories developed until 
the core themes emerged. To strengthen 
the validity of findings and ensure rigour, 
20% of all interviews were double-coded 
by a second member of the research team. 
Inconsistencies were resolved through 
discussion with a third author until a 
consensus on the final themes was reached.
RESULTS
In total, 33 interviews were completed: 
five with GPs and 28 with stroke survivors, 
14 of whom had a caregiver present. The 
characteristics of the stroke survivors are 
presented in Appendix 2.
Two key themes were identified. The 
first theme was patient level barriers and 
this included the subthemes ability to self-
care, how seriously people take stroke, 
and knowledge of stroke and medication. 
The second main theme was medication 
level barriers and this included subthemes 
beliefs about medication, taking secondary 
prevention medication, medication routines, 
changing medications, and regimen 
complexity and burden of treatment. 
Figure 1 shows the key themes and 
subthemes identified.
Patient level barriers
Ability to self-care. GPs admitted that 
being housebound was a significant barrier 
compromising patients care and affecting 
adherence:
‘If somebody is stuck at home, a total 5 hours 
they have got contact with somebody, the rest 
of the 365 days they are by themselves … their 
outcome is likely to be worse … their care can 
be low. If they’re depressed they won’t take 
their tablets.’ (GP05, male [M])
For many survivors, meanwhile, 
dependence on a caregiver for their 
knowledge and managing medication was 
important:
‘My wife sorts it out and that’s why I don’t 
know so much about it you see she [taps]. 
She puts them there, I take them and that’s 
it.’ (Patient [P] 04, M, 80 years)
How seriously people take stroke. Survivors 
and carers frequently trivialised stroke and 
the significance of symptoms, often due to 
How this fits in
Medication nonadherence is known to 
be problematic among stroke survivors, 
contributing to suboptimal health 
outcomes. Multiple barriers to medication 
adherence have been identified and 
characterised as specific to the individual, 
the medication, or the healthcare setting. 
This qualitative investigation of the attitudes 
of 28 survivors, 14 caregivers, and five 
GPs found patient barriers, such as their 
knowledge of stroke and medication, 
and medication barriers, such as patient 
beliefs about treatment, to be important. A 
collaborative approach is needed to address 
important barriers to medication adherence 
in UK general practice.
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a lack of knowledge and expectation around 
the condition:
‘I knew there was a problem but I thought 
perhaps it would go away. So you sort of 
erm bury your head in the sand.’ (P20, 
female [F], carer)
‘Within sort of half hour, hour at the most 
I felt I was ok again. The fact that we drove 
home the next day without seeking medical 
attention, it’s silly but I did it because I 
didn’t think anything else about it, it’s gone 
whatever it is.’ (P09, M, 68 years).
‘I wouldn’t take them because I still, to me, 
blood pressure and cholesterol tablets to 
me, I don’t see what they’re doing for me.’ 
(P24, M, 75 years).
In the absence of symptoms, the 
need for medication was also frequently 
underestimated, as GPs confirmed:
‘If they don’t see it or it didn’t leave any 
residual effect on them, then they tend to 
forget these things. Out of the sight, out of 
the mind.’ (GP02, F)
Knowledge of stroke and medication. 
Inadequate information on stroke 
prevention and recovery was frequently 
cited by patients and caregivers:
‘No, I don’t think we’ve got hardly any 
information. We haven’t ever really had a 
lot of information about it have we? You just 
sort of get on with it … I mean perhaps I 
haven’t ever asked enough but … I think you 
should be, told in advance.’ (P14, M, carer)
In addition, level of knowledge varied with 
several survivors admitting to being well-
informed, while others felt confused about 
tablets and the reasons they needed to take 
them:
‘The importance of taking these exactly on 
time is trivial. I would probably survive for 
a week, if I didn’t take them. For a month 
I’d probably survive. It would not make any 
difference in 2 days.’ (P03, M, 86 years)
‘I don’t know why I take them but it tells 
you on each one you know what it’s for … I 
wouldn’t say I know what they’re for.’ (P16, 
F, 82 years)
GPs agreed survivors lacked knowledge 
of medications but that many took tablets 
just because the doctor told them to:
‘I would say 50% of patients know what 
medication they are taking but erm 50% 
of patients doesn’t know, they think the 
doctors have prescribed me this medication 
and I have to take it and that’s why they are 
taking it.’ (GP02, F)
Medication level barriers
Beliefs about medication. Patients’ beliefs 
about medication frequently dictated 
adherence to some drugs:
‘I think aspirins are good for you. That’s the 
only one I fancy. Well it thins the blood and 
I think, well by thinning the blood it flows 
better and that stops any clots so I do like to 
take it. I just don’t see why I’m taking other 
medication, I’m not fat or anything like that. 
I don’t get very high blood pressure and 
well cholesterol, what is cholesterol?’ (P24, 
M, 75 years)
‘I refused it and … I said well … it’s not 
because it’s rat poisoning. If you tell me I’ve 
got warfarin I must be ill and if I take aspirin 
I can’t be that ill.’ (P22, F, 71 years)
Some survivors questioned the need for 
any medication, expressing doubts despite 
experiencing a stroke:
‘I mean I’m taking them because they know 
better than I do, but at the same time at the 
back of my head I’m thinking I, I shouldn’t 
have to take those.’ (P10, M, 66 years)
Some participants focused on conditions 
with a greater impact on everyday health:
‘To me the most important thing for her is 
controlling her diabetes … because I don’t 
want her passing out having a diabetes 
wobbly.’ (P08, M, 87 years)
Taking secondary prevention medication. 
The importance of taking stroke medication 
was widely acknowledged, however, total 
adherence was a minor concern for most:
STROKE
  Medication level barriers
 • Beliefs about medication
 • Taking secondary prevention medication
 • Medication routines
 • Changing medications
 • Regimen complexity and burden of 
    treatment
Patient level barriers
 • Ability to self-care
 • How seriously people take stroke
 • Knowledge of stroke and medication
Figure 1. Barriers to medication adherence among 
survivors of stroke/transient ischaemic attack.
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‘I’m sort of, a little bit annoyed that I’ve 
missed them but, no it doesn’t worry me. 
It would worry me if … I missed them for 3 
or 4 days but a day, no.’ (P10, M, 66 years)
Although most patients considered 
themselves adherent, many reported 
forgetting to take their night medication:
‘Well now and again I forget the cholesterol 
because that’s the one at night and it’s the 
only one I take at night.’ (P15, M, 67 years)
For some survivors, not taking 
medication was a conscious decision and 
GPs acknowledged they needed to respect 
this:
‘We do have to respect their autonomy at 
the end of the day it’s their bodies and some 
of them say to me look, for goodness sake 
I’m 94, I don’t want to take these tablets, it 
makes me feel ill. I do have to respect that.’ 
(GP01, F)
Nevertheless, survivors and caregivers 
reported they were generally happy to follow 
the advice of their GP:
‘So if the doctor says take ten pills a day, 
I’ll, I’ll do it … he makes the decision and 
erm he, he’s the boss man as you might 
say, who knows what he’s up to.’ (P08, M, 
87 years)
Patients also identified practical barriers 
including difficulties accessing medications 
and the size of tablets:
‘The big ones, I, do actually feel I have to 
swallow two or three times to get them 
down.’ (P10, M, 66 years)
‘Some of the, the pills are a hell of a trouble, 
you know the bubble wrap, flipping them 
out especially with my hands not as strong 
as they should be.’ (P08, M, 87 years)
Medication routines. Many patients 
admitted following a medication-taking 
routine, without which they would have 
difficulties with medication adherence:
‘I only remember to take the others be … if 
I take them out of the cupboard the night 
before and leave them on the top. If I didn’t 
take them out, I, I, would probably forget … 
because it isn’t the first thing that I think 
of … you know when I, when I first get up.’ 
(P10, M, 66 years)
The use of medication blister boxes was 
also beneficial and improved the experience 
of taking tablets:
‘ [Taking medication] that was a lot more hit 
and miss then … when you pop ‘em open 
if one flies on the floor I think, nah leave 
it. Sweep it up later on. It’s like a pleasure 
doing it now.’ (P06, M, 61 years)
Changing medications. Survivors of stroke 
described how medications were frequently 
changed, leading to disruption in pill 
administration and unwanted treatment 
side effects:
‘I did have a bad run because they changed 
the looks of the tablets oh god and I was 
taking four gout tablets a day and no 
diabetes ones and that put the old sugar 
up.’ (P13, M, 70 years)
‘They changed his medication to cheaper 
cholesterol and [he] was physically ill. He 
couldn’t cope on it at all so he went back 
and the doctor said “oh well it was just to 
try” and they put him back on the others.’ 
(P24, F, carer)
Regimen complexity and the burden of 
treatment. Survivors frequently expressed 
concerns around the burden of treatment 
with several describing how visiting the GP 
often resulted in additional medications:
‘I have to take 10 a day now altogether but 
I went up there [to the practice] to say can 
I get off some of these tablets, and I come 
back and I was on an extra one so I’ve not 
been up since.’ (P13, M, 70 years)
Others felt that the increased burden only 
contributed to their lack of understanding 
around stroke medications:
‘I’ve got yards of them. I don’t know half 
the names I’m just told when to take them. 
That’s one thing I’d like to do away with.’ 
(P11, M, 73 years)
GPs also acknowledged the burden 
of treatment and the contribution to 
patient’s negative attitudes towards taking 
medication:
‘Most of them are more unhappy about 
the number of tablets … from a patient’s 
perspective it’s usually it’s just physically a 
lot of tablets you have to swallow.’ (GP03)
Among the older patients, increased 
burden often led to a choice being made 
between which medications to take:
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‘Seventy per cent of patients are fully 
compliant but some of them are not 
compliant with these medications 
especially the elderly group of the patients 
because they think they are taking too many 
medications and so … they keep missing out 
the medications.’ (GP02, F)
DISCUSSION
Summary
A qualitative interview study was conducted, 
with survivors of stroke, caregivers, and 
GPs, to explore barriers to medication 
adherence in the UK general practice 
setting. Two key themes were identified. 
The first, patient level barriers, included the 
subthemes ability to self-care, knowledge 
of stroke and medication, and survivor’s 
tendency to trivialise stroke. The second key 
theme, medication level barriers, included 
the subthemes beliefs about how pills 
work, importance of taking medication, 
attitudes to missing tablets, difficulties 
taking medications, changing medication, 
and burden of treatment.
Strengths and limitations
An important strength was the inclusion 
of caregivers and GPs alongside patients, 
providing diversity of opinion. Employing 
a semi-structured interview methodology 
allowed participants maximum scope to 
dictate the direction of conversation and 
permitted an in-depth assessment of 
the topic area. This study offers a unique 
perspective on medication adherence 
barriers through the perceptions of stroke 
survivors, caregivers, and GPs. Due to the 
small number of GPs, it is unclear whether 
these views are representative of health 
professionals. Recruitment through five 
practices may have also limited the potential 
to generalise findings to the wider stroke 
population. Survivors were predominantly 
white, few were significantly disabled, and 
none had substantial cognitive impairment. 
Future research could include patients with 
aphasia who are dependent on others and 
patients from ethnic minorities in whom 
CVD is known to be prevalent.
Comparison with existing literature
Similar investigations from France and 
UK also reported that lack of symptoms 
and knowledge were important barriers to 
adherence.12,17 Poor knowledge contributed 
to misunderstanding, with stroke frequently 
trivialised and its symptoms ignored. This 
is perhaps not surprising, given that half of 
this study’s sample reported experiencing 
a TIA or mini-stroke, where symptoms 
usually disappear within 24 hours. Indeed, 
this absence of symptoms has often been 
identified as an important reason for the 
lack of urgency among survivors seeking 
help following stroke onset.18 Elsewhere, 
a systematic review of qualitative studies 
on patients’ understanding of hypertension 
and medication-taking identified side 
effects and a dislike of medication as key 
reasons for not continuing treatment.19
Lack of knowledge, doubts about 
treatment efficacy and prioritising 
medications are in line with previous work 
in which poor adherence was linked with 
being likely to question the purpose of 
medication, having a poor understanding 
of therapy and concerns around the lack 
of information provided by the health 
professional.20 Prioritising medications 
due to perceived importance and treating 
the most salient symptoms corresponds 
with patients performing a risk–benefit 
assessment, in which condition severity 
and knowledge of medication influence the 
decision to use treatment.21 The potential 
for positive beliefs on medication to 
influence subsequent behaviour suggest 
that exploring beliefs among survivors of 
stroke should be considered in an effort 
to improve medication adherence.22 The 
lack of knowledge identified among stroke 
survivors and caregivers suggests a need 
for improved education around stroke 
and treatment of the condition. Although 
education is a key component of providing 
stroke care, both survivors and caregivers 
face considerable barriers to information.23
The present investigation confirms 
previously reported barriers, including 
difficulties swallowing or accessing 
medication;8 frequent changing of 
medication;24 use of storage devices;25 
treatment complexity; and the influence 
of comorbidities.26 Complex medication 
regimens are important factors in 
adherence to chronic conditions, including 
hypertension and CVD.27 While reducing 
the daily medication dose can improve 
adherence to antihypertensives,28 recent 
research has suggested a fixed-dose 
combination (FDC) polypill can improve 
adherence to medications29 and address 
the barriers reported here.
These findings add to the growing body 
of literature on barriers to medication 
adherence in stroke. The failure of patients 
to act on stroke symptoms may represent a 
broader lack of knowledge associated with 
experiencing a TIA. Research into behaviour 
following a TIA indicates that a delay in 
seeking treatment is not uncommon, 
attributed not only to the recognition of 
symptoms but also the role of others and 
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interactions with the healthcare provider.30 
This study highlights the important role of 
the caregiver in providing information and 
facilitating medication-taking behaviour. 
Further work exploring the role of the 
caregiver is therefore warranted. Inadequate 
stroke knowledge and information provided 
by the GP has been reported previously, 
indicating there are significant unmet needs 
within this group.31 While the measurement 
of adherence was beyond the scope of the 
current study, exploring how the beliefs 
and perspectives of survivors reflect 
actual levels of adherence should also be 
considered. Determining how the barriers 
identified here relate to actual adherence 
may help determine where secondary 
prevention efforts should be focused in the 
future.
Implications for practice
These findings provide an important 
basis from where effective adherence 
interventions to improve stroke care may 
be developed and implemented in clinical 
practice. Interventions are needed to 
address barriers to medication adherence 
among survivors of stroke and ultimately 
improve stroke outcomes within this 
population. This study suggests that 
increased efforts to improve awareness of 
stroke and secondary prevention medication 
is warranted. Given their potentially 
significant role in managing medication, 
it is important that caregivers are fully 
engaged with efforts aimed at addressing 
barriers and improving adherence to 
stroke medication. It is likely that caregiver 
support may be important for maintaining 
adherence among those survivors with 
cognitive limitations, who were largely 
overlooked in the present study, and who 
may themselves face considerable barriers 
to adherence.
Adopting a collaborative approach 
between the patient, caregiver, and 
practitioner, as well as the wider primary 
healthcare team of practice nurses and 
pharmacists, who can also play a role 
in facilitating adherence, should be 
considered and can be a focus for future 
work in this area. Finally, developing the 
patient–practitioner relationship and 
facilitating better communication can 
enhance survivors’ understanding and 
knowledge of stroke and medication, while 
encouraging better adherence through 
challenging barriers to treatment.
In conclusion, important barriers to 
stroke medication adherence within UK 
general practice have been identified. 
Interventions are needed to address 
challenges associated with suboptimal 
adherence, including the provision of 
inadequate information, the role of the 
caregiver, recognition of stroke symptoms, 
patient beliefs about medication, and the 
burden of secondary prevention treatment. 
This investigation provides insight on the 
perspectives of practitioners, caregivers, 
and survivors, highlighting the complex and 
multifactorial barriers they face to stroke 
medication.
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Appendix 1. Interview schedule
Patient
1. Can you tell me about your health since you had your stroke?
• How would you say your health has changed?
• In what way, if any, has the stroke changed your relationship with your carer?
• Is there anything you find particularly difficult since you had your stroke?
2. Can you tell me about the stroke medication you currently take?
• What are your general feelings towards taking your current stroke medication?
• Do you know understand what the medications you take are for?
• How is your medication managed? Who is responsible? How does this work?
• Would you like to manage your own medication? Do you think this is an important role?
3. Taking your medication:
• Do you always take your medication when you’re supposed to?
•  Do you experience any other problems taking medication? Can you tell me a bit more about these problems? (for example, is quantity/size of meds a problem, 
etcetera).
• In what ways do you think the process of taking your medication could be improved?
Caregiver
1. Can you tell me about your experiences as a caregiver?
• What is this like day-to-day?
• How has this changed your relationship with the patient?
• What would you say has been most difficult about this experience of being a carer?
2. Do you manage the patient’s medication? If so, can you tell me a little bit about this role?
• Have you always managed their medication? If not, why?
• How important would you consider the role of managing this medication?
• How good is the patient at taking his/her medication?
•  Are there any difficulties around the taking of stroke medication. What do you think is the main concern the patient has? (for example, size, quantity, forgetting).
• How do you think the medication-taking process could be made easier/improved?
GP
1. What do you think of current treatment for secondary prevention of stroke?
• How do you think current stroke treatment/medication regimens could be improved?
• Do you think current regimens are easy for patients to understand/manage?
• Can you think of any limitations of current regimens for secondary prevention?
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Appendix 2. Interview participant characteristics
   Time since stroke/TIA,  
ID number Age, years Sex years Stroke classification Diabetic status Smoking status
P01 71 Female 18 Stroke Not diabetic Non-smoker
P02 65 Male 3 Stroke Diabetic Smoker
P03 86 Male 5 Stroke Not diabetic Non-smoker
P04 80 Male 2 TIA Not diabetic Ex-smoker
P05 64 Male 10 TIA Not diabetic Non-smoker
P06 61 Male 7 months TIA Diabetic Smoker
P07 67 Male 4.5 Stroke Not diabetic Non-smoker
P08 87 Male 2 TIA Diabetic Non-smoker
P09 68 Male 3 TIA Not diabetic Ex-smoker
P10 66 Male 3 TIA Not diabetic Ex-smoker
P11 73 Male 13 Stroke Not diabetic Ex-smoker
P12 67 Male 2 Stroke Diabetic Ex-smoker
P13 70 Male 10 TIA Diabetic Ex-smoker
P14 66 Female 6 Stroke Not diabetic Non-smoker
P15 67 Male 6 months Stroke Not diabetic Ex-smoker
P16 82 Female 4 months TIA Diabetic Non-smoker
P17 79 Male 10 TIA Not diabetic Non-smoker
P18 88 Male 12 Stroke Diabetic Non-smoker
P19 93 Male 10 TIA Not diabetic Non-smoker
P20 89 Male 2 TIA Not diabetic Non-smoker
P21 68 Female 3.5 Stroke Not diabetic Ex-smoker
P22 71 Female 9 TIA Not diabetic Non-smoker
P23 74 Female 5 TIA Not diabetic Non-smoker
P24 75 Male 2 Stroke Not diabetic Non-smoker
P25 76 Male 9 months Stroke Diabetic Ex-smoker
P26 72 Male 17 TIA Diabetic Non-smoker
P27 73 Male 2 Stroke Not diabetic Ex-smoker
P28 74 Female 4 Stroke Not diabetic Ex-smoker
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